Kodiak Sciences Inc(KOD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 7:51 PM ET (Korea 10/30 08:51)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -4.19 | Insider Own | 8.55% | Shs Outstand | 62.8M | Perf Week | 17.04% |
| Market Cap | 6.31B | Forward P/E | - | EPS next Y | 5.61% | Insider Trans | 53.89% | Shs Float | 57.5M | Perf Month | 5.91% |
| Enterprise Value | 6.34B | PEG | - | EPS next Q | -1.06 | Inst Own | 102.98% | Short Float | 14.79% | Perf Quarter | 141.46% |
| Income | -0.24B | P/S | - | EPS this Y | 5.58% | Inst Trans | 4.94% | Short Ratio | 5.04 | Perf Half Y | 130.91% |
| Sales | 0.00B | P/B | 103.25 | EPS next 5Y | 50.98% | ROA | -94.25% | Short Interest | 8.50M | Perf YTD | 259.08% |
| Book/sh | 0.97 | P/C | 50.12 | EPS past 3/5Y | 12.22% -8.23% | ROE | -368.37% | 52W High | -3.46% ($104.00) | Perf Year | 430.38% |
| Cash/sh | 2 | P/FCF | - | Sales past 3/5Y | - | ROIC | -118.6% | 52W Low | 534.1% ($15.83) | Perf 3Y | 6970.42% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -10.6% | Gross Margin | - | Volatility(W/M) | 6.18% 8.03% | Perf 5Y | -14.25% |
| Dividend TTM | - | EV/Sales | - | Sales Y/Y TTM | - | Oper. Margin | - | ATR (14) | 6.79 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 2.49 | EPS Q/Q | -1.85% | Profit Margin | - | RSI (14) | 68.07 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.49 | Sales Q/Q | - | SMA20 | 9.4% ($91.77) | Beta | 2.02 | Target Price | $121.67 |
| Payout | - | Debt/Eq | 2.5 | Earnings | 2026/8/13 | SMA50 | 60.55% ($62.54) | Rel Volume | 0.7 | Prev Close | $97.04 |
| Employees | 124 | LT Debt/Eq | 2.34 | EPS/Sales Surpr. | -9.78% - | SMA200 | 140.54% ($41.74) | Avg Volume(3M) | 1.69M | Price | $100.4 |
| IPO | 2018/10/4 | Option/Short | Yes/Yes | Trades | 15008 | Volume | 1,171,622 | Change | 3.46% |
🧬 This is a US clinical-stage biotech company developing therapeutics for retinal diseases. The company develops injectable treatments targeting retinal conditions that threaten vision, such as age-related macular degeneration and diabetic retinal diseases, and holds a candidate that extends dosing intervals to improve patient convenience. It is a biotech advancing into the ophthalmology market with differentiated durability technology and a leading late-stage clinical candidate.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded less than usual. That is 70% of its average volume.
KOD has a sound balance sheet but weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +5.6% this year.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -14.3%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 103.0%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #42 of 594 in the industry
Based on market cap of $6B.
FAQ
What kind of company is KOD?
KOD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KOD?
The market cap of KOD is approximately $6.3B, ranking 1,207 within its sector.
What is the 52-week high and low for KOD?
KOD has recorded a 52-week high of $104.00 and a low of $15.83.
